Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Arnold Kumpf is active.

Publication


Featured researches published by Robert Arnold Kumpf.


Journal of Medicinal Chemistry | 2016

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

Pei-Pei Kung; Eugene Rui; Simon Bergqvist; Patrick Bingham; John Frederick Braganza; Michael Raymond Collins; Mei Cui; Wade Diehl; Dac M. Dinh; Connie Fan; Valeria R. Fantin; Hovhannes J. Gukasyan; Wenyue Hu; Buwen Huang; Susan Kephart; Cody Krivacic; Robert Arnold Kumpf; Gary Li; Karen Maegley; Indrawan McAlpine; Lisa Nguyen; Sacha Ninkovic; Martha Ornelas; Michael Ryskin; Stephanie Scales; Scott C. Sutton; John Howard Tatlock; Dominique Verhelle; Fen Wang; Peter A. Wells

A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide torsion that improved the binding properties of the compounds was identified for this series via computational analysis. Cyclization of the amide linker resulted in a six-membered lactam analogue, compound 18. This transformation significantly improved the ligand efficiency/potency of the cyclized compound relative to its acyclic analogue. Additional optimization of the lactam-containing EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compound 31. Compound 31 displayed improved LipE and on-target potency in both biochemical and cellular readouts relative to compound 18. Inhibitor 31 also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.


Journal of the National Cancer Institute | 2004

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Christopher Calabrese; Robert J. Almassy; Stephanie Barton; Michael A. Batey; A. Hilary Calvert; Stacie Canan-Koch; Barbara W. Durkacz; Zdenek Hostomsky; Robert Arnold Kumpf; Suzanne Kyle; Jianke Li; Karen Maegley; David R. Newell; Elena Notarianni; Ian J. Stratford; Donald James Skalitzky; Huw D. Thomas; Lan-Zhen Wang; Stephen E. Webber; Kaye J. Williams; Nicola J. Curtin


Journal of Medicinal Chemistry | 2002

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

Canan Koch Ss; Thoresen Lh; Tikhe Jg; Karen Maegley; Robert J. Almassy; Jianke Li; Yu Xh; Zook Se; Robert Arnold Kumpf; Zhang C; Theodore James Boritzki; Mansour Rn; Zhang Ke; Ekker A; Christopher Calabrese; Nicola J. Curtin; Suzanne Kyle; Huw D. Thomas; Lan-Zhen Wang; Ah Calvert; Bernard T. Golding; Roger J. Griffin; David R. Newell; Stephen E. Webber; Zdenek Hostomsky


Journal of Medicinal Chemistry | 2004

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

Tikhe Jg; Stephen E. Webber; Zdenek Hostomsky; Karen Maegley; Ekkers A; Jianke Li; Yu Xh; Robert J. Almassy; Robert Arnold Kumpf; Theodore James Boritzki; Zhang C; Christopher Calabrese; Nicola J. Curtin; Suzanne Kyle; Huw D. Thomas; Lan-Zhen Wang; Ah Calvert; Bernard T. Golding; Roger J. Griffin; David R. Newell


Archive | 2014

BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS

Martin Paul Edwards; Robert Arnold Kumpf; Pei-Pei Kung; Indrawan McAlpine; Eugene Yuanjin Rui; Scott C. Sutton; John Howard Tatlock; Martin James Wythes


Archive | 2014

ARYL AND HETEROARYL FUSED LACTAMS

Martin Paul Edwards; Robert Arnold Kumpf; Pei-Pei Kung; Indrawan McAlpine; Sacha Ninkovic; Eugene Yuanjin Rui; Scott C. Sutton; John Howard Tatlock; Martin James Wythes; Luke Raymond Zehnder


Archive | 2015

ARYL FUSED LACTAMS AS EZH2 MODULATORS

Robert Arnold Kumpf; Pei-Pei Kung; Scott C. Sutton; Martin James Wythes


Archive | 2004

Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses

Larry Andrew Alegria; Klaus Ruprecht Dress; Buwen Huang; Robert Arnold Kumpf; Kathleen Kingsley Lewis; Jean Matthews; Sylvie Kim Sakata; Stacie Sara Canan-Koch; Christopher Scott Virgil


Journal of Medicinal Chemistry | 2017

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)

Pei-Pei Kung; Patrick Bingham; Alexei Brooun; Michael Raymond Collins; Ya-Li Deng; Dac M. Dinh; Connie Fan; Ketan S. Gajiwala; Rita Grantner; Hovhannes J. Gukasyan; Wenyue Hu; Buwen Huang; Robert Steven Kania; Susan Kephart; Cody Krivacic; Robert Arnold Kumpf; Penney Khamphavong; Manfred Kraus; Wei Liu; Karen Maegley; Lisa Nguyen; Shijian Ren; Daniel T. Richter; Robert A. Rollins; Neal W. Sach; Shikhar Sharma; John Sherrill; Jillian E. Spangler; Albert E. Stewart; Scott C. Sutton


Archive | 2016

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

John Howard Tatlock; Indrawan McAlpine; Michelle Bich Tran-Dube; Eugene Yuanjin Rui; Martin James Wythes; Robert Arnold Kumpf; Michele McTigue

Collaboration


Dive into the Robert Arnold Kumpf's collaboration.

Researchain Logo
Decentralizing Knowledge